Back to Search
JEFFREY SOSMAN, MD
MD
Medical Oncology Physician
NPI: 1699862706Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
036066401(IL)
Research & Publications (20)
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
PMID 11157013·J Clin Oncol·2001
3-trial
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production.
PMID 11091188·Br J Haematol·2000
3-trial
Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.
PMID 19679016·Curr Oncol Rep·2009
6-review
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
PMID 18467720·J Clin Oncol·2008
3-trial
Improving outcomes in patients with advanced renal cell carcinoma.
PMID 18366295·Expert Rev Anticancer Ther·2008
6-review
Opportunities and obstacles to combination targeted therapy in renal cell cancer.
PMID 17255307·Clin Cancer Res·2007
6-review
Molecular targets in melanoma from angiogenesis to apoptosis.
PMID 16609062·Clin Cancer Res·2006
6-review
Melacine: an allogeneic melanoma tumor cell lysate vaccine.
PMID 12903801·Expert Rev Vaccines·2003
6-review
Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy.
PMID 14569078·J Am Soc Nephrol·2003
6-review
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
PMID 11956267·J Clin Oncol·2002
3-trial
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
PMID 19402064·Cancer·2009
8-other
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PMID 19487381·J Clin Oncol·2009
3-trial
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
PMID 19139427·J Clin Oncol·2009
3-trial
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
PMID 18463792·Invest New Drugs·2008
3-trial
Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431).
PMID 18483359·Clin Cancer Res·2008
8-other
Prevention strategies for cardiovascular disease in HIV-infected patients.
PMID 18566315·Circulation·2008
8-other
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
PMID 18669461·J Clin Oncol·2008
3-trial
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
PMID 18792064·Cancer·2008
3-trial
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
PMID 19001327·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 675 N SAINT CLAIR ST STE 21-100
CHICAGO, IL 60611 - Phone
- (312) 695-0990
Quick Facts
- NPI
- 1699862706
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile